Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Scinai Immunotherapeutics Ltd(SCNI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SCNI
09/25/2026: SCNI (1-star) is currently NOT-A-BUY. Pass it for now.
Scinai Immunotherapeutics is a clinical-stage biotechnology company that has pivoted from vaccine development to focus on VHH antibody therapies for inflammatory diseases, supported by a specialized CDMO facility. The company's main strength is its proprietary nanobody technology and manufacturing capabilities, which it hopes will drive future value through licensing or service revenue. However, its history of clinical failure and high cash requirements present significant execution and financial risks. Investors should view this as a high-risk, speculative stock suited for those monitoring clinical data milestones and the company’s ability to secure sustainable CDMO partnerships in a competitive industry.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company's early-stage status and high risk profile may not offer the consistent growth metrics sought by typical growth investors. |
| Momentum investor | Weak fit | The stock has historically lacked sustained positive momentum required for this style. |
| Value investor | Weak fit | The lack of consistent earnings and assets makes valuation difficult and unattractive for traditional value investors. |
| Dividend investor | Weak fit | The company does not pay dividends and requires all cash for operations. |
| Low-risk investor | Weak fit | The company's high volatility and clinical risk profile are unsuitable for low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks often experience extreme price swings based on clinical news. |
| Valuation risk | High | Valuation is speculative as it relies entirely on the success of future clinical milestones. |
| Competition risk (immunology and CDMO competition) | High | The company faces immense pressure from larger, more efficient, and well-funded competitors. |
| Business quality | Low | The company is in a fragile state, attempting a turnaround after past operational failures. |
| Dividend income | Low / none | No dividend income is available for investors. |
| Execution risk | High | Successful transition to a new therapeutic focus and CDMO service model is highly uncertain. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -31.09% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.05M USD | Price to earnings Ratio 0.06 | 1Y Target Price 700 |
Price to earnings Ratio 0.06 | 1Y Target Price 700 | ||
Volume (30-day avg) 2.4M shares | Beta 2.08 | 52 Weeks Range 1.43 - 16.30 | Updated Date 09/27/2026 |
52 Weeks Range 1.43 - 16.30 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 28.07 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| CDMO Services | Manufacturing services provided to external biotech/pharma companies. | The company generates potential cash by manufacturing products for others. |
| Therapeutics R&D | Developing VHH-based drugs (licensing/future sales). | Future potential revenue depends entirely on successful drug development and licensing. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 0.06 | Forward PE - | Enterprise Value 7.89M | Price to Sales(TTM) 0.71 |
Enterprise Value 7.89M | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 5.31 | Enterprise Value to EBITDA 1.13 | Shares Outstanding 677.58K | Shares Floating 488.73K |
Shares Outstanding 677.58K | Shares Floating 488.73K | ||
Percent Insiders 14.16 | Percent Institutions 4.29 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Scinai Immunotherapeutics Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2015-05-12 | CEO & Director Mr. Amir Reichman M.B.A., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 45 | Website https://www.scinai.com |
Full time employees 45 | Website https://www.scinai.com | ||
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.